Phase 4 N=81 Artificial Tears, Tear Lipids and Tear Film Dynamics
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 Effects of Dry Eye Treatments on the Ocular Surface
Keratoconjunctivitis Sicca · Dry Eye Syndrome
Primary: Changes in Corneal Fluorescein Staining — 22.18; -3.35 units on a scale — p=<0.05
Phase 2 N=84 Dry Eye Disease Study With Brimonidine
Dry Eye
Primary: Tolerance of Test Substance Visual Analogue Scale (VAS) Score — 82.1; 87.0; 95.0; 91.1 score on a scale
Phase 4 N=51 Efficacy and Acceptability of Two Lubricant Eye Drops
Dry Eye Syndromes
Primary: Mean Frequency of Eye Drop Use Over 1 Week — 1.76; 1.66 Use per day
N/A N=47 Safety and Tolerability of Artificial Tears in Dry Eye Subjects
Dry Eye Syndrome
Primary: Tolerability Questionnaire Mean Scores at 1 Week — 70.1; 70.7; 57.3; 65.1 Scores on a scale
Phase 3 N=105 Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Dry Eye Syndrome
Primary: Global Ocular Staining (With Oxford Scale - Ranges : 0-15) — -2.5; -2.7 score on a scale
N/A N=32 Optive Brand For Day And Night Dry Eye Management
Dry Eye
Primary: Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score — -12.85 Scores on a scale — p=.001
Phase 3 N=535 Dry Eye Assessment and Management Study
Dry Eye
Primary: Mean of Change From Baseline in Ocular Surface Disease Index (OSDI) Score at 6 and 12 Months — -13.9; -12.5 units on a scale — p=0.40
N/A N=20 Acute Comfort of Lubricant Eye Drop FID 111421
Dry Eye
Primary: Drop Comfort Upon Instillation — 1.7; 1.3 Units on a scale
N/A N=316 Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye
Dry Eye Syndrome
Primary: Change From Baseline at Day 30 in Ocular Surface Disease Index© Questionnaire Score — 44; 45.2; -12.6; -13.6 Units on a scale
N/A N=57 Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
Dry Eye · Dry Eye Syndromes
Primary: Eye Dryness Score — 48 Score on Scale — p=0.0001
Phase 3 N=93 Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome
Dry Eye Syndromes
Primary: Global Ocular Staining (With Oxford Scale - Ranges :0-15) — -1.8; -2 scores on a scale
N/A N=40 Tolerability, Safety and Efficacy of Lubricin Versus Sodium Hyaluronate Eye Drops in Patients With Moderate Dry Eye
Dry Eye Syndrome
Primary: Change From Baseline in Foreign Body Sensation, Burning/Stinging, Itching, Pain, Stick Feeling, Blurred Vision, Photophobia and Total Ocular Tolerability Score (VAS)…
Phase 3 N=79 A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief
Dry Eye Syndromes
Primary: Tolerability Survey Score Using a 100 Unit Visual Analog Scale (VAS) in Period 1 — 255.74; 280.17; 284.89; 255.83 score on a scale
N/A N=161 Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Change From Baseline in Impact of Dry Eye on Everyday Life - Symptom Bother (IDEEL-SB) Questionnaire Score at Day 30 — -16.95 score on a scale — p=<.0001
N/A N=62 Efficacy, Safety of T2769 in Dry Eye Disease
Dry Eye Syndrome
Primary: Ocular Symptomatology — -55.9 units on a scale
N/A N=288 Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects
Dry Eye Syndrome
Primary: Change From Baseline in Subjective Evaluation of Symptom of Dryness (SESoD)Score at Day 90 — 2.7; 2.8; 2.8; -0.7 Scores on a Scale
Phase 4 N=51 Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®
Dry Eye Syndromes
Primary: Change From Baseline in the Total Corneal Staining Score With Fluorescein in the Worse Eye — 7.05; -1.51 score on a scale
N/A N=200 Impairment of Reading Ability in Dry Eye Patients
Dry Eye Syndromes
Primary: Sustained Silent Reading Speed — 248.4; 270.3 words/minute
Phase 4 N=70 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms
Dry Eye Syndromes
Primary: Change From Baseline in Ocular Surface Disease Index (OSDI) at Week 2 — 56.06; 54.292; -27.048; -28.303 Scores on a Scale
N/A N=20 Acute Comfort of Lubricant Eye Drops FID 112903
Dry Eye
Primary: Drop Comfort Upon Instillation — 1.1; 1.4 Units on a scale
Phase 4 N=15 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients
Glaucoma · Dry Eyes
Primary: Ocular Surface Staining — 1.65 units on a scale
Phase 3 N=400 Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
Dry Eye Disease (DED)
Primary: Change From Baseline in Total Staining Score at Day 90 in the Study Eye — -4.5; -3.4 score on a scale — p=0.0475
Phase 2 N=51 A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
Dry Eye Syndromes
Primary: Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale. — -0.81; -0.75; -0.82 units on a scale
N/A N=20 Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms
Dry Eye Syndrome
Primary: Change in Schirmer's Scores — -.30; -1.06 score on a scale
N/A N=10 Controlled Adverse Environment: A Pilot Study to Evaluate Tear Film Stability and Tear Evaporation
Environmental Exposure
Primary: Tear Evaporation Rate — 39.0; 44.8; 30.6; 26.7 Watt/meter^2
N/A N=20 Acute Comfort and Blurring Profile Evaluation of Marketed Lubricant Eye Drops
Dry Eye
Primary: Drop Comfort — 0.7; 1.05; 1.84; 1.1 units on a scale
Phase 4 N=55 Clinical Evaluation of Two Marketed Artificial Tears in Non-contact Lens Wearing Patients
Visual Acuity
Primary: Ocular Comfort — 81.96; 82.49 Units on a scale
Phase 4 N=178 Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED)
Ocular Hypertension · Open Angle Glaucoma
Primary: Change in Glaucoma Symptom Scale (GSS)-SYMP-6 Score — 1.7; 3.2 Units on a Scale — p=0.001
N/A N=40 Acute Comfort and Blur of Systane and Optive
Dry Eye
Primary: Visual Blur — 27.7; 33.55 Units on a scale